A recent study reveals that individuals who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt conventional lifestyle plans.
Research printed in a leading health publication points out that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these treatments must be aware of the danger of rapid weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
That rate of regain means a return to starting weight within about 18 months.
Weighing Approaches
The research, which examined dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who lose weight through lifestyle changes alone typically see a more gradual weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Doctors suggest the mode of action of the injections accounts for the heightened rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
Health authorities suggest the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of relapse, the treatment might need to be life-long.
This perspective is echoed by drug manufacturers, who note that the findings "underscore the chronic nature of excess weight," similar to managing diseases like hypertension.
Patient Experiences
People who have discontinued the jabs explain a powerful return of hunger.
"I experienced a trigger activating and you become starving," described an individual.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.
Significant Adoption
Survey data show that millions of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is higher among females than males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while the jabs are effective agents for weight loss, they are not a magic cure and long-term success likely depends on integrated behavioural management.
